Metastatic Squamous Cell Carcinoma of Prostatic Origin: Identification Through Next Generation Sequencing and Treatment With Pembrolizumab: A Case Report

Le résumé fourni par la source

Squamous cell carcinomas (SCCs) of prostatic origin are rare, representing 0.5% to 1% of all prostate carcinomas. They may be present at the diagnosis but are often discovered as a transformation of an adenocarcinoma previously treated with radiotherapy or androgen deprivation therapy. The few cases described in the literature indicate an aggressive evolution, with a median survival around 14 months. This case describes a 60-year-old man who initially had metastatic adenocarcinoma of prostatic origin that evolved toward a SCC. He was treated with chemotherapy followed by pembrolizumab for maintenance. The patient maintained a response for more than 2 years and died shortly after progression of his initial adenocarcinoma. The prostatic origin of the carcinoma was identified through next generation sequencing (NGS), a technology used for the rapid and throughout sequencing of the genome. Although there was a suspicion of transformation to SCC, the origin remained unclear until the NGS provided supporting evidence.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.